Table 1 Baseline characteristics of the study population
Variable | Control arm CVVHDF, n = 33 | Intervention arm CVVHD-HCO, n = 35 | p value |
|---|---|---|---|
Age, years | 67 [51,74.5] | 68 [57,74.0] | 0.626 |
Males | 26 (78.8%) | 18 (51.4%) | 0.180 |
Actual body weight, kg | 80 [72,100] | 80 [70,90] | 0.341 |
Height, cm | 174.70 ± 10.58 | 170.83 ± 9.16 | 0.113 |
BMI | 0.873 | ||
APACHE II score | 29.27 ± 7.27 | 29.60 ± 8.11 | 0.861 |
SOFA score | 9.15 ± 3.57 | 10.09 ± 3.88 | 0.305 |
SAPS II score | 56.27 ± 14.29 | 57.43 ± 14.63 | 0.743 |
Creatinine (µmol/l) | 240 [170,413] | 188 [129,266] | 0.031 |
Urea (mmol/l) | 19.90 ± 8.80 | 19.14 ± 8.99 | 0.728 |
urine output during first 24 h (ml) | 530 ± 752 | 518 ± 602 | 0.941 |
Admission diagnosis | |||
Sepsis | 9 (27.3%) | 11 (31.4%) | |
Pneumonia | 3 (9.1%) | 3 (8.6%) | |
ARDS | 3 (9.1%) | 4 (11.4%) | |
AKI | 2 (6.1%) | 3 (8.6%) | |
Hemorrhage | 4 (12.1%) | 1 (2.9%) | |
Cardiac | 4 (12.1%) | 5 (14.3%) | |
Rhabdomyolysis | 2 (6.1%) | 0 (0%) | |
Pancreatitis | 1 (3.0%) | 2 (5.7%) | |
Liver failure | 1 (3.0%) | 5 (14.3%) | |
Other | 4 (12.1%) | 1 (2.9%) | |
Systolic BP, mmHg | 108.33 ± 20.94 | 108.29 ± 20,04 | 0.992 |
MAP mmHg | 70 [62,78.5] | 72 [63,80] | 0.961 |
Mechanical ventilation | 24 (72.7%) | 33 (94.3%) | 0.16 |
Vasopressor | 23 (69.7%) | 32 (91.4%) | 0.23 |
Pre-existing diseases | |||
Congestive heart failure NYHA IV | 6 (18.2%) | 8 (22.9%) | 0.634 |
Pre-existing immunosuppression | 9 (27.3%) | 17 (48.6%) | 0.71 |
Liver cirrhosis | 7 (21.2%) | 10 (28.6%) | 0.484 |
History of malignancy | 7 (21.2%) | 11 (31.4%) | 0.34 |
Chronic pulmonary disease | 3 (9.1%) | 8 (22.9%) | 0.123 |
Indication for RRT | |||
Metabolic acidosis | 5 (15.2%) | 12 (34.3%) | 0.069 |
Pulmonary edema | 12 (36.4%) | 15 (42.9%) | 0.584 |
Hyperpotassemia | 8 (24.2%) | 7 (20%) | 0.673 |
Anuria (< 100 ml/d) | 26 (78.8%) | 25 (71.4%) | 0.484 |
Uremia | 20 (60%) | 13 (37.1%) | 0.53 |
Main reason for AKI | |||
Septic | 13 (39.4%) | 19 (54.3%) | |
Postrenal | 0 (0%) | 0 (0%) | |
Cardiorenal | 4 (12.1%) | 5 (14.3%) | |
Toxic | 3 (9.1%) | 0 (0%) | |
Hypovolemia | 6 (18.2%) | 3 (8.6%) | |
Rhabdomyolysis | 3 (9.1%) | 0 (0%) | |
Hepatorenal | 2 (6.1%) | 5 (14.3%) | |
Other | 2 (6.1%) | 3 (8.6%) |